SG Americas Securities LLC Acquires 33,375 Shares of BioNTech SE (NASDAQ:BNTX)

SG Americas Securities LLC boosted its stake in BioNTech SE (NASDAQ:BNTX) by 412.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 41,470 shares of the company’s stock after purchasing an additional 33,375 shares during the quarter. SG Americas Securities LLC’s holdings in BioNTech were worth $4,726,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of BioNTech during the second quarter valued at about $2,892,000. Point72 Asset Management L.P. grew its holdings in shares of BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares during the period. Caxton Associates LP purchased a new position in shares of BioNTech in the 2nd quarter valued at approximately $682,000. Employees Retirement System of Texas lifted its stake in shares of BioNTech by 15.7% in the 2nd quarter. Employees Retirement System of Texas now owns 30,388 shares of the company’s stock valued at $2,442,000 after purchasing an additional 4,115 shares during the period. Finally, Scientech Research LLC bought a new stake in shares of BioNTech during the second quarter valued at approximately $1,127,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Price Performance

NASDAQ BNTX opened at $118.14 on Friday. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The stock has a 50-day moving average of $115.78 and a 200 day moving average of $105.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $28.32 billion, a price-to-earnings ratio of -56.26 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the previous year, the company earned $0.73 earnings per share. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. On average, sell-side analysts forecast that BioNTech SE will post -3.77 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BNTX shares. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. HC Wainwright reissued a “buy” rating and set a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Finally, Truist Financial initiated coverage on BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.